Aprea Therapeutics (APRE) News Today → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free APRE Stock Alerts $4.77 +0.16 (+3.47%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | msn.comAprea Therapeutics Advances Cancer Treatment Trial to Higher Dose LevelMay 29, 2024 | americanbankingnews.comAprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 64.3% in MayMay 28, 2024 | globenewswire.comAprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical TrialMay 15, 2024 | msn.comAprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug TrialsMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: Aprea Therapeutics’ Financial and Clinical ProgressMay 14, 2024 | investorplace.comAPRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comAprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business UpdateMay 13, 2024 | globenewswire.comAprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare ConferenceMay 2, 2024 | markets.businessinsider.comAprea Therapeutics Appoints Mirza As CMOMay 2, 2024 | finance.yahoo.comAprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | globenewswire.comAprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.April 26, 2024 | finance.yahoo.comInterim Report - January-March 2024April 12, 2024 | markets.businessinsider.comAprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy RatingApril 10, 2024 | globenewswire.comAprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024April 3, 2024 | msn.comAprea Therapeutics files to sell 4.39M shares of common stock for holdersMarch 28, 2024 | markets.businessinsider.comAprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy RatingMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024March 26, 2024 | investorplace.comAPRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023March 26, 2024 | globenewswire.comAprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateMarch 20, 2024 | markets.businessinsider.comAprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug PipelineMarch 18, 2024 | msn.comAprea Therapeutics Secures Up to $34 Million in Groundbreaking Financing DealMarch 16, 2024 | uk.investing.comAprea Therapeutics CFO buys $7,362 in company stockMarch 16, 2024 | uk.investing.comAprea Therapeutics director buys $50k of company stockMarch 15, 2024 | insidertrades.comOren Gilad Acquires 2,000 Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) StockMarch 14, 2024 | finance.yahoo.comKarolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 millionMarch 14, 2024 | globenewswire.comKarolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 millionMarch 12, 2024 | markets.businessinsider.comAprea Therapeutics Secures Private Placement Financing Of Upto $34 MlnMarch 11, 2024 | msn.comWhy Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?March 11, 2024 | msn.comAprea Therapeutics announces private placement financing of up to $34MMarch 11, 2024 | globenewswire.comAprea Therapeutics Announces Private Placement Financing of up to $34.0 MillionMarch 11, 2024 | globenewswire.comAprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing CancersMarch 5, 2024 | globenewswire.comAprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024February 23, 2024 | uk.investing.comAprea Therapeutics Inc (APRE)February 7, 2024 | thestreet.comAprea Therapeutics Inc.February 7, 2024 | msn.comAprea Therapeutics Updates Corporate Presentation MaterialsFebruary 6, 2024 | finance.yahoo.comAprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase InhibitorJanuary 31, 2024 | msn.comBiotechnology Center in Doylestown Seeks State Funding to Continue Support for Life Science Start-UpsJanuary 30, 2024 | finance.yahoo.comAprea Therapeutics to Present at DDR Inhibitors Summit 2024January 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aprea Therapeutics Amid Strong Clinical Results and Strategic AdvantagesJanuary 10, 2024 | finance.yahoo.comWill Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?January 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), Enanta Pharmaceuticals (ENTA)December 9, 2023 | markets.businessinsider.comMaxim Group Keeps Their Hold Rating on Brainstorm Cell Therapeutics (BCLI)November 17, 2023 | markets.businessinsider.comCapricor Therapeutics: Solid Financials and Promising DMD Trial Progression Support Buy RatingNovember 12, 2023 | markets.businessinsider.comVistaGen Therapeutics’ Robust Financial Position and Promising Pipeline Underpin Buy Rating: A Comprehensive AnalysisNovember 11, 2023 | markets.businessinsider.comPromising Clinical Data and Financial Performance Validate Buy Rating for Aprea Therapeutics: An Analysis by Robert DriscollNovember 9, 2023 | msn.comAprea Therapeutics GAAP EPS of -$0.86November 9, 2023 | finance.yahoo.comAprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateOctober 20, 2023 | marketbeat.comTrading was temporarily halted for "APRE" at 09:10 AM with a stated reason of "LULD pause."October 20, 2023 | marketbeat.comTrading was temporarily halted for "APRE" at 09:10 AM with a stated reason of "LULD pause."October 16, 2023 | markets.businessinsider.comPositive Outlook for Aprea Therapeutics: Promising Developments and Safety Profile of ATRN-119 Bolster Buy Rating Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. APRE Media Mentions By Week APRE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APRE News Sentiment▼0.510.76▲Average Medical News Sentiment APRE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APRE Articles This Week▼51▲APRE Articles Average Week Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ENLV News Today APLM News Today ONCT News Today NNVC News Today BOLT News Today BIOR News Today IPA News Today JAN News Today LSTA News Today VIRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APRE) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
